Attenuation of methylglyoxal-induced peritoneal fibrosis: Immunomodulation by interleukin-10

Laboratory Investigation

Volumn 95, Issue 12, 2015, Pages 1353-1362

  Onishi, Akira ^a   Akimoto, Tetsu ^a   Urabe, Masashi ^a   Hirahara, Ichiro ^a   Muto, Shigeaki ^a   Ozawa, Keiya ^a   Nagata, Daisuke ^a   Kusano, Eiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD68 ANTIGEN; CYTOKERATIN; ENHANCED GREEN FLUORESCENT PROTEIN; GELATINASE A; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; METHYLGLYOXAL; PARVOVIRUS VECTOR; PERITONEAL DIALYSIS FLUID; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION; HISTOPATHOLOGY; IMMUNOMODULATION; MALE; MESOTHELIUM CELL; NONHUMAN; PERITONEAL FIBROSIS; PERITONEUM ADHESION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADENOVIRIDAE; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENE THERAPY; GENETICS; IMMUNOLOGY; PERITONEUM; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ADENOVIRIDAE; ANIMALS; BODY WEIGHT; DISEASE MODELS, ANIMAL; GENETIC THERAPY; IMMUNOMODULATION; INTERLEUKIN-10; MALE; PERITONEAL FIBROSIS; PERITONEUM; PYRUVALDEHYDE; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY;

EID: 84948464220     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2015.110     Document Type: Article

References (44)

1. Onishi A, Akimoto T, Morishita Y et al. The role of concurrent renal dysfunction. Am J Nephrol 2014;40:381-390
2. Krediet RT. 30 years of peritoneal dialysis development: the past and the future. Perit Dial Int 2007;27(Suppl 2):S35-S41
3. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis. Perit Dial Int 2003;23:530-541
4. Mortier S, Faict D, Schalkwijk CG et al. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004;66:1257-1265
5. Lai KN, Tang SC, Leung JC. Mediators of inflammation and fibrosis. Perit Dial Int 2007;27(Suppl 2):S65-S71
6. Hirahara I, Kusano E, Yanagiba S et al. Peritoneal injury by methylglyoxal in peritoneal dialysis. Perit Dial Int 2006;26:380-392
7. Hirahara I, Ishibashi Y, Kaname S et al. Methylglyoxal induces peritoneal thickening by mesenchymal-like mesothelial cells in rats. Nephrol Dial Transplant 2009;24:437-447
8. Ahmed MU, Brinkmann Frye E, Degenhardt TP et al. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 1997;324(Pt 2):565-570
9. Ogura M, Urabe M, Akimoto T et al. Interleukin-10 expression induced by adeno-associated virus vector suppresses proteinuria in Zucker obese rats. Gene Therapy 2012;19:476-482
10. Nakagome K, Dohi M, Okunishi K et al. In vivo IL-10 gene delivery attenuates bleomycin induced pulmonary fibrosis by inhibiting the production and activation of TGF-beta in the lung. Thorax 2006;61: 886-894
11. Mu W, Ouyang X, Agarwal A et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. J Am Soc Nephrol 2005;16:3651-3660
12. Shi MN, Huang YH, Zheng WD et al. Relationship between transforming growth factor beta1 and anti-fibrotic effect of interleukin-10. World J Gastroenterol 2006;12:2357-2362
13. Nonaka-Sarukawa M, Okada T, Ito T et al. Adeno-associated virus vector-mediated systemic interleukin-10 expression ameliorates hypertensive organ damage in Dahl salt-sensitive rats. J Gene Med 2008;10:368-374
14. Hirata H, Miyamoto H, Shimokawa K et al. Novel diagnostic method of peritoneal injury using dual macromolecular markers. Biol Pharm Bull 2014;37:262-267
15. Li MC, He SH. IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J Gastroenterol 2004;10:620-625
16. Schnepp BC, Clark KR, Klemanski DL et al. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol 2003;77: 3495-3504
17. Ito T, Okada T, Miyashita H et al. N. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. Circ Res 2007;101:734-741
18. Urabe M, Ding C, Kotin RM. Insect cells as a factory to produce adenoassociated virus type 2 vectors. Hum Gene Ther 2002;13:1935-1943
19. Urabe M, Nakakura T, Xin KQ et al. Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect cells. J Virol 2006;80:1874-1885
20. Zolotukhin S, Byrne BJ, Mason E et al. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Therapy 1999;6:973-985
21. Suzumura K, Hirano T, Son G et al. Adeno-associated virus vectormediated production of hepatocyte growth factor attenuates liver fibrosis in mice. Hepatol Int 2008;2:80-88
22. Nishino T, Miyazaki M, Abe K et al. Antisense oligonucleotides against collagen-binding stress protein HSP47 suppress peritoneal fibrosis in rats. Kidney Int 2003;64:887-896
23. Yanez-M M, Lara-Pezzi E, Selgas R et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003;348:403-413
24. Holness CL, Simmons DL. Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood 1993;81:1607-1613
25. Iwazu Y, Muto S, Fujisawa G et al. Spironolactone suppresses peritubular capillary loss and prevents deoxycorticosterone acetate/ salt-induced tubulointerstitial fibrosis. Hypertension 2008;51:749-754
26. Nakayama M, Sakai A, Numata M et al. Hyper-vascular change and formationof advanced glycation endproducts in the peritoneum caused by methylglyoxal and the effect of an anti-oxidant, sodium sulfite. Am J Nephrol 2003;23:390-394
27. Imai T, Hirahara I, Morishita Y et al. DNA microarray analysis of the epithelial-mesenchymal transition of mesothelial cells in a rat model of peritoneal dialysis. Adv Perit Dial 2011;27:11-15
28. Aroeira LS, Aguilera A, Sanchez-Tomero JA et al. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol 2007;18: 2004-2013
29. Di Paolo N, Sacchi G. Atlas of peritoneal histology. Perit Dial Int 2000;20 (Suppl 3):S5-96
30. Pecoits-Filho R, Stenvinkel P, Wang AY et al. Chronic inflammation in peritoneal dialysis: the search for the holy grail? Perit Dial Int 2004;24: 327-339
31. Fujimori A, Naito H, Miyazaki T et al. Elevation of interleukin 6 in the dialysate reflects peritoneal stimuli and deterioration of peritoneal function. Nephron 1996;74:421-472
32. Topley N, Jrres A, Luttmann W et al. Human peritoneal mesothelial cells synthesize interleukin-6: induction by IL-1 beta and TNF alpha. Kidney Int 1993;43:226-233
33. Offner FA, Feichtinger H, Stadlmann S et al. Transforming growth factor-beta synthesis by human peritoneal mesothelial cells. Induction by interleukin-1. Am J Pathol 1996;148:1679-1688
34. Webster L, Abordo EA, Thornalley PJ et al. Induction of TNF alpha and IL-1 beta mRNA in monocytes by methylglyoxal-and advanced glycated endproduct-modified human serum albumin. Biochem Soc Trans 1997;25:250S
35. Pal A, Bhattacharya I, Bhattacharya K et al. Methylglyoxal induced activation of murine peritoneal macrophages and surface markers of T lymphocytes in sarcoma-180 bearing mice: involvement of MAP kinase, NF-kappa beta signal transduction pathway. Mol Immunol 2009;46:2039-2044
36. Margetts PJ, Kolb M, Yu L et al. Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 2002;160:2285-2294
37. Moore KW, de Waal Malefyt R, Coffman RL et al. Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001;19:683-765
38. Mazighi M, Pell A, Gonzalez W et al. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004;287:H866-H871
39. Shi JH, Guan H, Shi S et al. Protection against TGF-β1-induced fibrosis effects of IL-10 on dermal fibroblasts and its potential therapeutics for the reduction of skin scarring. Arch Dermatol Res 2013;305:341-352
40. Mactier RA. The spectrum of peritoneal fibrosing syndromes in peritoneal dialysis. Adv Perit Dial 2000;16:223-228
41. Lambie ML, John B, Mushahar L et al. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 2010;78:611-618
42. Habib AM, Preston E, Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant 2010;25:1633-1638
43. Montz FJ, Holschneider CH, Bozuk M et al. Interleukin 10: ability to minimize postoperative intraperitoneal adhesion formation in a murine model. Fertil Steril 1994;61:1136-1140
44. Hirahara I, Ogawa Y, Kusano E et al. Activation of matrix metalloproteinase-2 causes peritoneal injury during peritoneal dialysis in rats. Nephrol Dial Transplant 2004;19:1732-1741